Tradestie Institutional Equity Comparison Engine

IBRX vs MRNA โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

MRNA Overall Edge

MRNA Captures Institutional Edge (2โ€“2 Pillars ยท 6โ€“4 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Moderna, Inc. Common Stock (MRNA) driven by superior Valuation, Momentum & Technical while IBRX counters with relative strength in Growth & Margin, Options & Structure. Fundamentally, IBRX trades at 60.2x Forward P/E with -150.2% operating margin (+52.3% YoY revenue) versus MRNA at 23.0x Forward P/E and -80.8% operating margin (+29.2% YoY). In options structure, IBRX sits in BREAKDOWN (14th %ile IV; Dealer Gamma Walls on Pro) against MRNA sits in CONSOLIDATION (52nd %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner MRNA
IBRX 60.2x vs MRNA 23.0x Fwd P/E
Growth & Margin Winner IBRX
Op Margin -150.2% vs -80.8% ยท YoY +52.3% vs +29.2%
Momentum & Technical Winner MRNA
1Y +181.3% vs +706.5% ยท 52W Pos 39% vs 67%
Options & Structure Winner IBRX
BREAKDOWN (14th %ile IV) vs CONSOLIDATION (52nd %ile IV)
IBRX NASDAQ
ImmunityBio, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$6.02
-8.37% 1D
Market Cap $7.0B
1M Return -27.56%
1Y Return +181.31%
Forward P/E 60.2x
Unified AI Score
61.4 / 100 BUY
Tech 75.0 Fund 69.0 Flow 69.0 Mom 60.0
MRNA NASDAQ
Moderna, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$195.00
-2.17% 1D
Market Cap $80.7B
1M Return -3.77%
1Y Return +706.45%
Forward P/E 23.0x
Unified AI Score
40.3 / 100 SELL
Tech 18.0 Fund 42.0 Flow 67.0 Mom 46.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: IBRX +181.31% MRNA +706.45% Spread: +525.14 pp (MRNA Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period IBRX Revenue MRNA Revenue IBRX Op. Margin MRNA Op. Margin Margin Edge
FY2018 $0M $140M -209338.3% -306.0% MRNA
FY2019 $0M $60M -7095.9% -906.8% MRNA
FY2020 $0M $800M -36509.1% -95.0% MRNA
FY2021 $0M $18.5B -35361.9% 72.0% MRNA
FY2022 $0M $19.3B -146374.2% 48.9% MRNA
FY2023 $0M $6.85B -58239.5% -61.9% MRNA
FY2024 $10M $3.24B -2334.2% -121.9% MRNA
FY2025 $110M $1.94B -226.0% -158.1% MRNA

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: IBRX (4) vs MRNA (6)
Institutional Metric IBRX MRNA Criterion Row Winner
Market Capitalization Scale $7.0B $80.7B Larger Scale MRNA
Trailing P/E Ratio Valuation 60.2x 23.0x Lower Multiple MRNA
Forward P/E Ratio Valuation 60.2x 23.0x Lower Multiple MRNA
Revenue Growth (YoY) Growth +52.3% +29.2% Higher Growth IBRX
Operating Margin (TTM) Profitability -150.2% -80.8% Higher Margin MRNA
Net Profit Margin Profitability 0.0% -110.5% Higher Margin IBRX
Return on Equity (ROE) Capital Efficiency 0.0% -34.5% Higher ROE IBRX
52-Week Range Position Momentum 39% ($2โ€“$12) 67% ($22โ€“$281) Stronger Trend MRNA
Beta / 30D Volatility Risk Regime 1.68ฮฒ ยท 107% Vol 2.23ฮฒ ยท 78% Vol Lower Realized Risk MRNA
Unified Institutional Score Composite Signal 61.4 / 100 (BUY) 40.3 / 100 (SELL) Higher Composite IBRX

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full IBRX vs MRNA Buy Guide
IBRX BREAKDOWN
30d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 14th %ile
IV Regime Compressed (<25th %ile)
Live IBRX Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
MRNA CONSOLIDATION
22d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 52nd %ile
IV Regime Balanced (25thโ€“60th %ile)
Live MRNA Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither IBRX nor MRNA registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.